VTRS

Viatris Inc. is a global pharmaceutical company that develops, manufactures and markets a broad range of prescription medicines, including generic drugs, off‑patent branded products, biosimilars and selected specialty assets. The firm was created in 2020 through the merger of Mylan and Pfizer’s Upjohn business, combining Mylan’s extensive generics platform with Upjohn’s legacy branded portfolio and worldwide distribution network. Operating in the healthcare and pharmaceuticals sector, Viatris serves more than 165 countries and holds a portfolio of over 1,400 approved molecules, positioning it as one of the largest providers of affordable, established‑medicine treatments worldwide. Notable aspects of its strategy include expanding access to medicines, leveraging a global supply chain, and pursuing selective acquisitions to strengthen specialty and ophthalmology capabilities.